About
Granalix BioTechnologies was established to develop innovative, science-based formulations of natural antioxidants that can be used for the prevention and treatment of neurodegenerative conditions. The company's first product, GranaGard, is a submicron self-emulsion formulation of pomegranate seed oil, which contains high concentrations of punicic acid (PA), one of the strongest natural antioxidants. In the GranaGard formulation, PA has been shown to convert in vivo into conjugated linoleic acid, an established neuroprotector and mitochondrial activity modulator. GranaGard was shown to delay disease onset in a mouse model of genetic prion disease, which presents neurodegenerative features reminiscent of Alzheimer's disease, as well as to reduce disease burden in a mouse model of multiple sclerosis. All components of GranaGard are generally regarded as safe by the FDA.
Headcount over time
Q&A
- What is Granalix BioTechnologies' primary focus?
- Granalix BioTechnologies focuses on developing innovative, science-based formulations of natural antioxidants for the prevention and treatment of neurodegenerative conditions.
- What is Granalix BioTechnologies' flagship product?
- Granalix BioTechnologies' first product is GranaGard, a submicron self-emulsion formulation of pomegranate seed oil, rich in punicic acid (PA).
- How does GranaGard work?
- GranaGard's formulation allows punicic acid (PA) to convert in vivo into conjugated linoleic acid, which is a neuroprotector and mitochondrial activity modulator.
- What conditions has GranaGard shown efficacy against in preclinical models?
- GranaGard has been shown to delay disease onset in a mouse model of genetic prion disease, which has features similar to Alzheimer's, and to reduce disease burden in a mouse model of multiple sclerosis.
- What is the employee count for Granalix BioTechnologies?
- Granalix BioTechnologies has 1-10 employees.
- When was Granalix BioTechnologies founded?
- Granalix BioTechnologies was founded in May 2013.
- Where is Granalix BioTechnologies headquartered?
- Granalix BioTechnologies is headquartered in Jerusalem, Jerusalem District, Israel.
- What is Granalix BioTechnologies' primary sector?
- Granalix BioTechnologies operates in the Health Tech & Life Sciences sector.
Team · 4
Sectors & technology
Highlights
Tags
Full data — links, identifiers, deals & radar signals (jobs, patents, research, more)
External links
| Website | il.granalix.com |
|---|---|
| linkedin.com/company/17933204 | |
| facebook.com/Granalix-331240673885848 | |
| YouTube | youtube.com/channel/UC5LKpelR_YawKn0tyHMx1DQ |
Identifiers & details
| Legal name | Granalix Bio Technologies Ltd |
|---|---|
| Founded | 2013-5 |
| Employees (exact) | 9 |
Radar intelligence
GitHub
| Top repos | Front-End, BackEnd, .github, support |
|---|
Web history (Wayback)
| Domain | il.granalix.com |
|---|
Certificate / subdomain footprint
| Subdomains | 1 |
|---|
Israeli Companies Registrar (רשם החברות / ICA)
| Registrar # (ח.פ.) | 514925205 |
|---|---|
| Status | פעילה |
| Corp type | ישראלית חברה פרטית |
| Incorporated | 2013-05-23 |
| Purpose | לעסוק בכל עיסוק חוקי |
| Liability | מוגבלת |
| In violation (unfiled) | no |
| Last annual report | 2026 |
| Active charges / liens | 0 |
| Registry events | 0 |
| Registered address | יד חרוצים 6 ירושלים |